Showing results (851-860 of 932) with videos related to

Sort By:
Pageof 94
Bioorganic & Medicinal Chemistry Letters|July 1, 2008
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituentGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
International Journal of Cancer|October 5, 2006
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeuticsZehan Chen, Zhan Xiao, Wen-Zhen Gu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunityPhilip D Bardwell, Jijie Gu, Donna McCarthy, et al.
Neurogenetics|March 20, 2008
Detection of low-level somatic and germline mosaicism by denaturing high-performance liquid chromatography in a EURO-MRX family with SLC6A8 deficiencyOfir T Betsalel, Jiddeke M van de Kamp, Cristina Martínez-Muñoz, et al.
Journal of Medicinal Chemistry|April 5, 2002
Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluationLe Wang, Keith W Woods, Qun Li, et al.
Lung Cancer (Amsterdam, Netherlands)|August 29, 2006
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinomaHelen J Ross, Lowell L Hart, Paul M Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsJoann P Palma, Yi-Chun Wang, Luis E Rodriguez, et al.
Cancer Immunology Research|June 5, 2014
Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapyEsther P M Tjin, Gabrielle Krebbers, Kimberley J Meijlink, et al.
NAR Cancer|November 29, 2024
RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft modelsFrancien Talens, Vivian Oliviera Nunes Teixeira, Yannick P Kok, et al.
Gut|February 14, 2018
Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatmentLisanne S Rigter, Petur Snaebjornsson, Efraim H Rosenberg, et al.
Pageof 94